Reata Pharmaceuticals Inc - Ordinary Shares - Class A

NASDAQ:RETA  
78.85
-7.08 (-8.24%)
Earnings Announcements

Reata Pharmaceuticals Inc Announces Q3 2021 Financial Results, Provides An Update On Clinical Development Programs

Published: 11/08/2021 11:47 GMT
Reata Pharmaceuticals Inc - Ordinary Shares - Class A (RETA) - Reata Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results and Provides an Update on Clinical Development Programs.
Q3 Non-GAAP Loss per Share $1.27.
Q3 GAAP Loss per Share $1.97.
at September 30, 2021, We Had Cash and Cash Equivalents of $713.2 Million.
Reaffirm Current Cash Runway to Last Through Mid-2024.
Q3 Earnings per Share View $-2.17 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $1.63 Million
Adjusted EPS is expected to be -$2.36

Next Quarter Revenue Guidance is expected to be $1.14 Million
Next Quarter EPS Guidance is expected to be -$2.42

More details on our Analysts Page.